Blockchain Registration Transaction Record

GeoVax Advances Marburg Virus Vaccine Development in Pandemic Preparedness Efforts

GeoVax Labs, Inc. strengthens its pandemic preparedness and biodefense vaccine portfolio with the advancement of a Marburg virus vaccine. Learn about the promising results and implications of this development in addressing critical public health and biodefense needs.

The development of a vaccine against Marburg virus by GeoVax is crucial in addressing highly fatal endemic threats and biodefense needs worldwide. With no licensed vaccines currently available for Marburg, GeoVax's progress signifies a significant step towards mitigating the public health and biodefense risks posed by hemorrhagic fever viruses. The innovative MVA platform utilized by GeoVax has the potential to elicit durable immune responses, positioning the company as a key player in pandemic preparedness and biodefense.